Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne is viewed favorably because its best-in-class protein reagents franchise sits in a segment with durable demand, while its diagnostics and genomics portfolio adds exposure to molecular diagnostics and spatial biology. It is also the most levered name to a biotech funding rebound, with about 20% of sales tied to emerging biotech and roughly 15% of sales expected to come from cell therapy after Wilson Wolf, which could add more than 100 basis points to structural growth. Management’s self-help actions, including the late CY2025 divestiture of Exosome Diagnostics and brand consolidation from 10 to 3, should support margin expansion in FY2026 even before demand fully recovers.

Bio-Techne is facing a bearish setup because its downside case assumes another year of challenged growth, multiple compression, and a valuation reset if the acquisition does not close. Investors remain worried that end-market demand in life science tools may take longer to recover, while share loss could intensify as acquired rivals like PeproTech, Abcam, and BioLegend gain larger parents and more resources. The company’s exposure to cell therapy success at about 15% of sales, mixed M&A execution, and the risk that AI-driven shifts away from wet-lab research could pressure its core business all support a negative fundamental outlook.